HPA053243

antibody from Atlas Antibodies

Targeting: HBEGF DTR, DTS, HEGFL

Immunohistochemistry (Data presented on provider website)

Antibody Data

Product number

HPA053243

Provider

Atlas Antibodies

Proper citation

Atlas Antibodies Cat#HPA053243, RRID:AB_2682086

Product name

Anti-HBEGF

Antibody type

Polyclonal

Description

Polyclonal Antibody against Human HBEGF, Gene description: heparin-binding EGF-like growth factor, Alternative Gene Names: DTR, DTS, HEGFL, Validated applications: IHC, Uniprot ID: Q99075, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Reactivity

Human

Host

Rabbit

Conjugate

Unconjugated

Isotype

IgG

Vial size

100 µl

Concentration

0.1 mg/ml

Storage

Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Handling

The antibody solution should be gently mixed before use.

References

Submitted references

A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study

Bergström S, Öijerstedt L, Remnestål J, Olofsson J, Ullgren A, Seelaar H, van Swieten J, Synofzik M, Sanchez-Valle R, Moreno F, Finger E, Masellis M, Tartaglia C, Vandenberghe R, Laforce R, Galimberti D, Borroni B, Butler C, Gerhard A, Ducharme S, Rohrer J, Månberg A, Graff C, Nilsson P, Jiskoot L, Rowe J, de Mendonça A, Tagliavini F, Santana I, Le Ber I, Levin J, Danek A, Otto M, Frisoni G, Ghidoni R, Sorbi S, Pasquier F, Jelic V, Andersson C, Afonso S, Almeida M, Anderl-Straub S, Antonell A, Archetti S, Arighi A, Balasa M, Barandiaran M, Bargalló N, Bartha R, Bender B, Benussi A, Benussi L, Bessi V, Binetti G, Black S, Bocchetta M, Borrego-Ecija S, Bras J, Bruffaerts R, Cañada M, Cantoni V, Caroppo P, Cash D, Castelo-Branco M, Convery R, Cope T, Di Fede G, Díez A, Duro D, Fenoglio C, Ferrari C, Ferreira C, Fox N, Freedman M, Fumagalli G, Gabilondo A, Gasparotti R, Gauthier S, Gazzina S, Giaccone G, Gorostidi A, Greaves C, Guerreiro R, Heller C, Hoegen T, Indakoetxea B, Jiskoot L, Karnath H, Keren R, Langheinrich T, Leitão M, Lladó A, Lombardi G, Loosli S, Maruta C, Mead S, Meeter L, Miltenberger G, van Minkelen R, Mitchell S, Moore K, Nacmias B, Nicholas J, Olives J, Ourselin S, Padovani A, Panman J, Papma J, Peakman G, Pievani M, Pijnenburg Y, Polito C, Premi E, Prioni S, Prix C, Rademakers R, Redaelli V, Rittman T, Rogaeva E, Rosa-Neto P, Rossi G, Rosser M, Santiago B, Scarpini E, Schönecker S, Semler E, Shafei R, Shoesmith C, Tábuas-Pereira M, Tainta M, Taipa R, Tang-Wai D, Thomas D, Thompson P, Thonberg H, Timberlake C, Tiraboschi P, Todd E, Van Damme P, Vandenbulcke M, Veldsman M, Verdelho A, Villanua J, Warren J, Wilke C, Woollacott I, Wlasich E, Zetterberg H, Zulaica M
Molecular Neurodegeneration 2021;16(1)

---

Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer

Khelwatty S, Essapen S, Bagwan I, Green M, Seddon A, Modjtahedi H
Oncotarget 2019;10(18):1704-1715

---

Heparin‐binding epidermal growth factor‐like growth factor promotes neuroblastoma differentiation

Gaviglio A, Knelson E, Blobe G
The FASEB Journal 2017;31(5):1903-1915

---

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer

Khelwatty S, Essapen S, Bagwan I, Green M, Seddon A, Modjtahedi H
Oncotarget 2016;8(5):7666-7677